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Variability and sex‑dependence 
of hypothermic neuroprotection 
in a rat model of neonatal 
hypoxic–ischaemic brain injury: 
a single laboratory meta‑analysis
thomas R. Wood1,4, Julia K. Gundersen1, Mari Falck1, Elke Maes1, Damjan Osredkar1,5, 
Else Marit Løberg2, Hemmen Sabir1,6, Lars Walløe1 & Marianne Thoresen1,3*
Therapeutic hypothermia (HT) is standard care for term infants with hypoxic–ischaemic (HI) 
encephalopathy. However, the efficacy of HT in preclinical models, such as the Vannucci model of 
unilateral HI in the newborn rat, is often greater than that reported from clinical trials. Here, we report 
a meta-analysis of data from every experiment in a single laboratory, including pilot data, examining 
the effect of HT in the Vannucci model. Across 21 experiments using 106 litters, median (95% CI) 
hemispheric area loss was 50.1% (46.0–51.9%; n = 305) in the normothermia group, and 41.3% 
(35.1–44.9%; n = 317) in the HT group, with a bimodal injury distribution. Median neuroprotection by 
HT was 17.6% (6.8–28.3%), including in severe injury, but was highly-variable across experiments. 
Neuroprotection was significant in females (p < 0.001), with a non-significant benefit in males 
(p = 0.07). Animals representing the median injury in each group within each litter (n = 277, 44.5%) 
were also analysed using formal neuropathology, which showed neuroprotection by HT throughout 
the brain, particularly in females. Our results suggest an inherent variability and sex-dependence 
of the neuroprotective response to HT, with the majority of studies in the Vannucci model vastly 
underpowered to detect true treatment effects due to the distribution of injury.
The use of animal research has dramatically advanced human knowledge of physiology, pathology, and science-
based  medicine1. However, despite centuries of improvement in the methodological and ethical approaches to 
experiments involving  animals1, preclinical research across all fields of medicine has also significantly under-
performed with regards to the translation of robust treatments for complex diseases in  humans2.
For perinatal asphyxia and subsequent hypoxic–ischaemic encephalopathy (HIE), just one treatment so far, 
therapeutic hypothermia (HT), has emerged from the preclinical research to provide a robust treatment effect in 
term newborns with moderate-to-severe neurological  injury3. A recent meta-analysis of those clinical trials found 
that the numbers needed to treat (NNT) were 11 to reduce mortality, and 8 to reduce major neurodevelopmental 
 disability3. However, HT is not universally neuroprotective. Meta-analyses of the original large clinical trials of 
HT found that 40–50% of treated infants still experienced a poor outcome (death or severe disability)4, though 
more recent trials suggest it is now around 30%5.
In the most widely-researched model of neonatal hypoxic–ischaemic (HI) brain injury, the Vannucci model of 
unilateral HI, our group and others have traditionally found that HT provides around 40% reduction in neuropa-
thology score and tissue  loss6–9. This neuroprotective effect of HT was corroborated in larger animal  models10–12, 
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leading to incremental pilot studies in term newborn asphyxiated neonates, which formed the basis of large 
clinical  trials13–18. The use of HT for infants with moderate-to-severe HIE can therefore be acknowledged as one 
of the few success stories of translational research for neurological diseases. Despite this, the neuroprotective 
effect of HT in preclinical studies remains generally greater than that seen clinically, and a number of possible 
explanations for this gap have been postulated. This includes the generally heterogeneous clinical population 
compared to highly-standardised animal models, as well as the fact that HT may not be beneficial after severe 
HI brain injury, or in the setting of certain types of systemic  inflammation6,19–21. It is also generally accepted that 
published preclinical studies are more likely to show positive results than negative, and the low power of studies 
using small treatment groups is likely to exaggerate treatment  benefits22.
Here, we aim to address some of these problems by collating and analysing all experiments in our standard-
ised Vannucci rat model of unilateral HI brain injury in postnatal-day seven (P7) rats. The data spans a 3-year 
period employing the standard P7 Vannucci model in our laboratory. It includes all pilot data, as well as results 
from published studies, where an HT treatment group was included. The aim is to gain a greater insight into the 
usefulness and limitations of the model itself, as well as the effects of HT, and discuss a framework for future 
work investigating neonatal HIE in animal models.
Methods
Study design. From January 2013 to February 2016, experiments examining the effects of HT were per-
formed 21 times in our laboratory as part of various experimental treatment protocols. All successfully-com-
pleted experiments that included our “standard” moderate HI injury (described below), a control normothermia 
(NT) group and HT group, were included in the analysis. Data from a total of 106 litters with 1,042 pups was 
available from 21 experiments that had both an NT control group and standard HT treatment group (Table 1). 
Results from one set of five consecutive experiments (experiment numbers 7–11, n = 126 animals; NT n = 62; 
HT n = 64) were previously  published6. All other experiments (numbers 1–6 and 12–21) were previously unpub-
lished. Ten of the 21 experiments included one or more other treatment groups in addition to the standard NT 
and HT groups as part of a number of pilot experiments. Animals from these groups were not included in the 
analysis. A total of 420 pups were excluded from this analysis. This included 51 pups that died during ligation 
Table 1.  Severity of injury and hypothermic neuroprotection. Median (95% CI) percent area loss in the 
NT and HT groups, and percent neuroprotection in the HT group, across all 21 experiments. The median 
difference in area loss between the two groups (median NT–median HT) was used to calculate percent 
neuroprotection in the HT group. Overall median area loss, median difference, and percent neuroprotection 
were calculated by combining all the animals in the NT (n = 305) and HT (n = 317) groups. The degree of 
neuroprotection provided by HT was not correlated with initial injury severity (median area loss in the NT 
group; Kendall’s τb, p = 0.83). As a potential factor associated with experimental variability, local barometric 
pressure on the morning of each experiment is also provided. Data from experiments 7–11 was previously 
 published6.
Exp Date






(mmHg)NT (N =) HT (N =)
1 10/01/2013 42.4 (28.2–51.4) 16 44.4 (27.2–49.9) 14 − 2.0 − 4.7 761
2 08/02/2013 29.8 (5.5–43.1) 14 19.8 (2.5–26.9) 14 10.0 33.5 763.5
3 18/03/2014 33.7 (9.8–50.5) 11 47.6 (37.1–52.0) 13 − 13.9 − 41.2 748.5
4 25/04/2014 10.6 (1.9–21.5) 15 20.3 (2.3–22.9) 15 − 9.7 − 92.4 769.6
5 15/05/2014 48.6 (26.4–58.1) 11 27.9 (5.5–41.0) 13 20.7 42.7 773.2
6 13/06/2014 45.2 (25.9–56.4) 13 54.8 (36.7–58.7) 14 − 9.6 − 21.3 760.7
7 14/08/2014 58.3 (29.5–62.8) 10 37.2 (9.2–46.5) 10 21.1 36.2 750.3
8 21/08/2014 58.7 (45.4–63.2) 10 54.3 (6.0–59.8) 10 4.4 7.5 751.1
9 28/08/2014 37.8 (5.2–52.2) 12 24.1 (0.0–37.4) 14 13.7 36.4 761.2
10 11/09/2014 53.8 (34.1–60.0) 18 33.6 (15.2–39.5) 18 20.2 37.5 767.6
11 23/10/2014 33.2 (6.7–45.1) 12 23.2 (2.4–33.1) 12 10.0 30.1 762.8
12 30/10/2014 36.6 (22.7–48.2) 15 32.1 (21.3–40.6) 17 4.5 12.4 766.1
13 28/11/2014 54.0 (33.8–58.7) 12 46.2 (27.3–53.3) 12 7.8 14.3 771.9
14 12/05/2015 43.0 (13.7–58.1) 10 25.7 (0.8–28.7) 12 17.3 40.2 755.4
15 18/06/2015 44.5 (27.2–51.0) 17 34.4 (20.7–41.5) 18 10.1 22.7 751.8
16 19/08/2015 27.7 (8.0–33.8) 15 19.6 (4.2–27.3) 17 8.1 29.4 770.4
17 27/08/2015 47.7 (28.8–56.4) 16 46.9 (29.2–57.4) 17 0.8 1.7 751.1
18 14/10/2015 39.0 (29.1–48.1) 20 40.7 (27.7–48.1) 22 − 1.7 − 4.4 773.4
19 12/11/2015 56.5 (38.9–59.3) 22 39.0 (27.7–50.3) 19 17.5 30.9 753.4
20 19/11/2015 50.3 (33.9–54.6) 17 44.3 (27.7–50.6) 18 6.0 11.8 743.5
21 07/01/2016 38.9 (23.2–43.0) 19 42.0 (32.4–47.5) 18 − 3.1 − 7.9 761.2
Overall 50.1 (46.0–51.9) 305 41.3 (35.1–44.9) 317 8.8 17.6
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(n = 30), hypoxia (n = 12), or the survival period (n = 9). An additional 369 pups were excluded because they 
carried temperature probes during HI and treatment (n = 108), or due to being in treatment groups other than 
standard NT and HT (n = 261). The final number of included animals was n = 622 (n = 329 females, n = 293 
males). Survival was always 1 week. Two-to-four of the same five experienced investigators (TRW, MF, EM, DO, 
and HS) performed the surgical and experimental procedures in every experiment.
Animals. All experimental protocols were reviewed and approved by the University of Oslo’s animal ethics 
research committee. The methods described below were carried out in accordance with those approved proto-
cols, as well as the University of Oslo’s ethical guidelines regarding the use of experimental animals. Within each 
experiment, 3–7 litters of 8–12 Wistar rat pups of both sexes (33–70 pups per day) underwent unilateral HI. 
Pups and dams were either bred in house or sourced from external breeders (Charles River, Sulzfeld, Germany; 
Taconic Biosciences, Ejby, Denmark). Each experiment either used (1) pregnant dams, who were transported to 
our institution 1 week before their expected due date or (2) litters of sex-balanced pups, which were delivered 
24–48 h before the experiment. Before and after HI and treatment, pups were housed with their dams in an ani-
mal facility with a 12:12 h dark:light cycle at 21 °C environmental temperature. Food and water were provided 
ad libitum, and pups were checked for health daily.
Moderate Vannucci model of unilateral hypoxia–ischaemia. The effects of hypothermia on neona-
tal HI brain injury were assessed using a modified Vannucci model of unilateral HI in P7 rat pups, as previously 
 described6,23. On P7, pups underwent ligation of the left carotid artery under anaesthesia, with 3% isoflurane in a 
2:1 gas mixture of  NO2/O2, via a nose cone. After recovering under a heat lamp, pups were returned to the dams 
for at least 30 min before being exposed to 8% oxygen for 90–100 min at 36 °C rectal temperature in a specially-
designed  chamber6,24. This length of hypoxia produces a “moderate” injury, with around 30–50% loss of the 
left hemisphere compared to the right hemisphere in the NT  group6,20. As both ischaemia and superimposed 
hypoxia are required to induce brain injury in this neonatal rat model, the right (unligated and contralateral) 
hemisphere remains undamaged, and can act as an internal  control6,23. During hypoxia, core temperature was 
continuously recorded in each chamber in “sentinel” pups carrying a rectal temperature probe (IT-21, Phys-
itemp Instruments, Clifton, NJ, USA). Rectal temperature was maintained within ± 0.2 °C of the target using 
a servo-controlled water-filled mat (CritiCool, MTRE, Yavne, Israel) inside the chamber, with another animal 
holding a surface skin temperature probe. Rectal temperatures were manually recorded during all experiments 
and collated in 10 min epochs. In P7 rats, rectal temperature correlates within 0.1 °C with brain  temperature7. 
All surgeries and hypoxia periods occurred between 6 a.m. and 12 p.m. local time on the specified experimental 
day (Table 1). Local atmospheric pressure during each experimental period was retrospectively collected from 
www.timea nddat e.com and www.yr.no.
Hypothermia treatment. Before hypoxia, pups were randomised to treatment by litter, weight, and sex. 
In this model, NT refers to 37 °C, with HT treatment occurring at 32 °C (HT32)24–26. Immediately after hypoxia, 
pups were transferred to chambers at the allotted temperature. Rectal temperature was maintained within 
± 0.2 °C of the target, as described above. After 5 h of the allocated treatment, pups were removed from the treat-
ment chambers and returned to the  dams20.
Tissue harvesting and processing. Tissue harvesting and processing was performed as previously 
 described6,20,27–29. At P14, rats were sacrificed via transcardiac perfusion with saline and 10% neutral-buffered 
formalin under isoflurane/N2O anaesthesia. Brains were harvested and kept in 10% neutral-buffered formalin 
for 4 days until further processing. Six coronal 3 mm blocks were cut through the brain using a standard rat brain 
matrix (ASI Instruments Inc., Warren, MI, USA), and embedded in paraffin.
Area loss analysis. Area loss analysis was performed as previously  described6,20. For each animal, one 5 μm 
slide each from the two blocks best representing the cortex, hippocampus, basal ganglia and thalamus were 
taken (one at the level of the frontal cortex, and one at the mid-hippocampal level), and stained with haema-
toxylin and eosin (H&E). Slides were scanned (Epson Perfection V750 Pro), and virtual slides were exported 
as 600dpi images. The optical density and hemispheric area of each section was analysed with ImageJ software 
(ImageJ, version 1.46r, National Institutes of Health, Bethesda, MD, USA) by an individual who was blinded to 
group allocation. For each section, the area of each hemisphere was calculated, and the percentage area loss of 
the left hemisphere relative to the right hemisphere determined by using the following formula: (1 − (area left/
area right)) × 100. Two sections were analysed for each animal, and individual area loss was reported as the mean 
of the area loss across the two analysed sections. In this model, computer-assessed percent hemispheric area loss 
using this method has previously been shown to be highly correlated with formal neuropathology assessment 
and specific area and neuronal loss within the  hippocampus6,20.
pathological injury assessment. In order to confirm that area loss analysis accurately reflected formal 
pathology, a subset of slides underwent pathological scoring by an investigator blinded to treatment allocation. 
Within each litter from each experiment, the animals displaying the median area loss from the two treatment 
groups were scored. If there were an even number of animals from a given litter in a treatment group, the two 
rats around the median were chosen. Using the same slides analysed for area loss, the left side of the brain was 
examined and four areas of the brain were  scored (cortex, basal ganglia, thalamus and hippocampus) by an 
investigator blinded to the treatment allocation, as previously  described25 The severity of damage was graded 
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from 0.0 (no injury) to 4.0 (maximum injury, see Thoresen et al.7 and Dalen et al.26), with intervals of 0.5 for each 
of the 4 regions, giving a 9-step scale of pathology. Results were analysed based on individual region as well as an 
average of the scores from these regions, giving a global pathology score.
Statistical analysis. Only the NT and HT groups from each experiment were used in this analysis. Pups 
used as rectal and skin temperature probes were also excluded because the stress of restraint has previously been 
shown to have a neuroprotective effect in this  model30. Statistical analyses were performed using GraphPad 
Prism version 8.4 (GraphPad Software, La Jolla, CA, USA), and RStudio version 1.2.5 (RStudio, Boston, MA, 
USA). Within each experiment, the median difference between groups (with 95% confidence intervals, CI) and 
percent neuroprotection provided by HT were calculated. The CIs of median differences between groups were 
calculated according to the method of Bonnet and  Price31. Percent neuroprotection in the HT group relative to 
the NT group was calculated with the following formula:
The presence of severe injury in an individual animal was defined as > 60% area loss, as previously described in an 
adapted “severe” injury model that included increasing hypoxia time to 150 min, and intra-hypoxic temperature 
to 37 °C, resulting in a median 60% area loss in the NT  group20. The median percent area loss, and percent neu-
roprotection, in the NT and HT groups were calculated by combining the data from all experiments and treating 
them as single groups of 305 and 317 animals, respectively. Comparison of area loss between the two groups, both 
overall and split by sex, was performed by calculating the weighted and summed difference of expected versus 
observed total ranks within each experiment using the Wilcoxon–van Elteren test. Between-group comparisons 
of regional and global pathology score were carried out with a two-sided Wilcoxon–Mann–Whitney U-test with 
Bonferroni adjustment for multiple comparisons. Linear regression was used to compare area loss with global 
pathology score. For overall area loss and global pathology score a Cohen’s d effect size (ES) was calculated using 
the Mann–Whitney U statistic and transformation of η2 according to the methods of Lenhard and  Lenhard32–34. 
To determine how many animals might be required in each group to find the overall ES of HT detected here, 
a post hoc power calculation was performed using G*Power version 3.135.The ES was entered into G*Power, 
along with the following parameters: α = 0.05, β = 0.8, comparison test = two-tailed Wilcoxon–Mann–Whitney 
U-test. This resulted in a predicted number of animals that would be required in each group to detect the corre-
sponding ES. Within the NT and HT groups, Spearman’s r correlation matrices were constructed to examine the 
association between experimental factors and area loss. Experimental factors that were significantly associated 
with area loss in these unadjusted correlations were then entered into two logistic regression models to predict 
dichotomous outcome: (1) whether an animal in the NT group had area loss greater than the median area loss 
across all experiments, and (2) whether an animal in the HT group experienced neuroprotection (e.g. had an 
area loss below the median area loss in the NT group within that experiment). Regression models are reported 
with parameter estimates and 95% CI, as well as overall accuracy. Kendall’s tau-b (τb) correlation coefficient was 
calculated when examining the effect of individual experimental variables on percent area loss and neuroprotec-
tion by HT. A two-sided p value < 0.05 was considered statistically significant.
Results
included data. Data from a total of 622 animals from 106 litters (NT, n = 305; HT, n = 317 animals) were 
included in the final analysis. Median (range) NT or HT group size in each individual experiment was 14.5 
(10–22) animals. In addition to area loss assessment, a total of n = 277 (44.5%) of animals underwent formal 
pathological scoring. These were selected as the 1–2 animals representing the median NT and HT area loss in 
each litter within each experiment. The median number of litters in each experiment was n = 5 (range n = 3–7). 
Animal characteristics from each experiment (numbered in chronological order) are summarised in Supple-
mental Table S1.
Area loss and hypothermic neuroprotection after moderate HI. Across the 21 experiments, 
median (95% CI) area loss was 50.1% (46.0–51.9%; n = 305) in the NT group, and 41.3% (35.1–44.9%; n = 317) 
in the HT group (Fig. 1a). Plotting the cumulative frequencies in each group with increasing area loss suggested 
a relatively uniform degree of neuroprotection across the whole range of injury severity, particularly between 
10 and 60% area loss (Fig. 1b). For each experiment, the median area loss in the NT and HT groups, median 
difference between the two groups, and percent neuroprotection in the HT group, is listed in Table 1. Median dif-
ference (NT–HT) area loss in each individual experiment ranged from − 13.9 to 21.1%, with an overall median 
difference (95% CI) of 8.8% (3.4–14.2%) between the two groups (Fig.  2). Percent neuroprotection (median 
difference as a percentage of area loss in the NT group) ranged from − 92.4 to 42.7%, with an overall median of 
17.6% (6.8–28.3%) neuroprotection in the HT group compared to the NT group. Within each experiment, the 
degree of neuroprotection provided by HT was not correlated with initial injury severity (median area loss in the 
NT group; Kendall’s τb = 0.038, p = 0.83). HT appeared to be similarly neuroprotective across the range of injury, 
with the NNT (number needed to treat) to prevent an incidence of > 60%, > 50%, > 40%, > 30%, and > 20% areas 
loss being 10.0, 5.8, 8.2, 9.8, and 12.8, respectively.
Regional and global pathology scoring. In the 44.5% of animals that underwent formal pathology 
scoring (n = 277; n = 132 NT, n = 145 HT), median (95% CI) global pathology score was 3.4 (3.3–3.7) in the 
NT group, and 2.4 (2.0–2.8) in the HT group (p < 0.001; Fig. 3a). Similar to area loss, plotting the cumulative 
frequencies in each group with increasing pathology showed neuroprotection across the whole range of injury 
Percent Neuroprotection = (MedianNT−MedianHT)/MedianNT × 100
5
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:10833  | https://doi.org/10.1038/s41598-020-67532-2
www.nature.com/scientificreports/
severity, with the greatest difference between groups at a global pathology score of 3.0 (Fig. 3b). Regional pathol-
ogy scores in the NT group were 4.0 (3.5–4.0) in the hippocampus, 3.5 (3.0–4.0) in the thalamus, 3.0 (2.5–3.5) 
in the basal ganglia, and 3.65 (3.3–3.8) in the cortex (Supplemental Figure S1). Significant neuroprotection was 
seen in all regions in the HT group, with corresponding scores of 2.0 (2.0–3.0) in the hippocampus (p < 0.001), 
Figure 1.  Hypothermic neuroprotection. (a) Scatter plot of percent area loss in the NT (n = 305) and HT 
(n = 317) groups. The median with 95% CI is plotted adjacent to each scatter. Across the 21 experiments, median 
(95% CI) area loss in was 50.1% (46.0–51.9%; n = 305) in the NT group, and 41.3% (35.1–44.9%; n = 317) in 
the HT group. *Denotes significant neuroprotection (p < 0.001). (b) Cumulative frequency plot from the NT 
(n = 305) and HT (n = 317) groups, with each observation resulting in a proportional increase in the y-axis. 
A relatively uniform degree of neuroprotection is seen across the whole range of injury severity, particularly 
between 10 and 60% area loss.
Figure 2.  Median difference in area loss between NT and HT. Median difference (with 95% CI) in area loss 
between the NT and HT groups in each individual experiment, and overall. Experiments are numbered in 
chronological order. Of the 21 experiments, 15 favoured HT, and the overall median difference (absolute 
reduction in area loss in the HT group) was 8.8% (3.4–14.2%).
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2.5 (2.0–3.0) in the thalamus (p = 0.007), 2.0 (1.5–2.0) in the basal ganglia (p = 0.001), and 3.0 (2.3–3.0) in the 
cortex (p = 0.003).
Area loss versus global pathology scoring—effect size and power analysis. The overall Cohen’s 
d ES for the effect of HT on area loss was 0.29 in the entire cohort. Assuming a non-normal parent distribution, 
α = 0.05, β = 0.2 and balanced group sizes, n = 218 animals per group would be required to detect the true ES 
of HT on area loss. In the subset of animals that underwent pathology scoring, median (95% CI) area loss was 
51.0% (47.0–54.6%) in the NT group, and 41.3% (31.6–45.6%) in the HT group (Fig. 4a). In animals analysed 
for both area loss and pathology, HT therefore resulted in 19.0% neuroprotection when analysed using area loss, 
which was increased to 25% neuroprotection when comparing the same animals using global pathology score. 
The corresponding ES for HT was 0.42 when using area loss, and 0.51 when using global pathology, resulting in 
a predicted n = 105 and n = 71 animals per group being required to detect the ES using area loss and pathology, 
respectively. Global pathology score was linearly correlated with area loss in both the NT  (R2 = 0.94, p < 0.001) 
and HT  (R2 = 0.90) groups (Fig. 4b).
Experimental variables. The variability in injury of the Vannucci model is well-documented6,9. To explore 
factors that might be associated with experimental variability, Spearman’s rank correlation matrices were con-
structed for both the NT and HT group to assess whether individual area loss was significantly associated with 
any of the following variables: sex, weight at P7, ligation time, delay between ligation and hypoxia, litter size 
(number of animals in the litter after HI until P14), and barometric pressure during HI (Supplemental Fig-
ures S2A and S2B). Median (range) barometric pressure during HI was 761.2 mmHg (743.5–773.4 mmHg). In 
both the NT and HT groups, barometric pressure during HI displayed a small but significant association with 
area loss (Supplemental Fig. 3A). The magnitude of the association was similar in both groups (Kendall’s τb: 
NT = −0.105, p = 0.008; HT = −0.109, p = 0.005), with higher barometric pressures associated with lower area 
loss. When grouped by quintiles of intra-experimental barometric pressure (n = 58–68 animals per group per 
quintile), a nadir of area loss was seen in both groups in the 4th quartile (763.5–769.6 mmHg; Supplemental 
Fig. 3B). However, barometric pressure during HI was not associated with degree of individual neuroprotection 
provided by HT as measured by each HT animal’s percent neuroprotection relative to the median NT area loss 
for that experiment (Kendall’s τb = 0.026, p = 0.5). In the NT group only, litter size was inversely associated with 
area loss (Kendall’s τb = −0.151, p < 0.001; Supplemental Fig. 3C), with P7 weight associated with area loss in the 
HT group only (Kendall’s τb = 0.081, p = 0.03; Supplemental Fig. 3D).
Median (IQR) carotid ligation time (period under anaesthesia during ligation) was 6 (5–6) minutes in the 
NT group, and 6 (5–6) minutes in the HT group. Ligation time did not affect area loss (Data not shown). Median 
(IQR) time between ligation and hypoxia was 119 (95–146) minutes in the NT group, and 122 (95–146) minutes 
in the HT group. Delay between ligation and hypoxia was not correlated with injury or effect of hypothermia 
(Supplemental Figure S3E). No correlation between the source (vendor) of the animals and the individual experi-
mental outcomes were seen. Weight at P7 and P14 was similar in both groups, as was total weight gain (data 
Figure 3.  Global pathology scoring. (a) In the subset of animals that underwent formal pathology scoring 
(n = 277; n = 132 NT, n = 145 HT), median (95% CI) global pathology score 3.4 (3.3–3.7) in the NT group, and 
2.4 (2.0–2.8) in the HT group. *Denotes significant neuroprotection (p < 0.001). (b) Cumulative frequency plot 
from the NT (n = 132) and HT (n = 145) groups, with each observation resulting in a proportional increase in 
the y-axis. A relatively uniform degree of neuroprotection is seen across the whole range of injury severity, with 
increasing relative neuroprotection in the HT group up to a global pathology score of 3.0.
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not shown). An inverse correlation between weight gain and area loss at P14 was seen in both the NT and HT 
groups (Kendall’s τb: NT = −0.257, HT = −0.316; p < 0.01 for both; Supplemental Figure S3F). Rectal temperature 
monitoring indicated that in all experiments target temperatures were achieved within 10 min and remained 
stable throughout (Supplemental Figure S4).
Barometric pressure and parameters associated with area loss in the correlation matrixes—either litter size 
(NT group) or P7 weight (HT group)—were entered into two logistic regression models to predict: (1) whether 
an animal in the NT group had area loss greater than the median area loss across all experiments (50.1%), and 
(2) whether an animal in the HT group experienced neuroprotection (had an area loss below the median area 
loss in the NT group within that experiment). The regression for the NT group was able to predict above median 
area loss with an accuracy of 60.3% (Supplemental Table S2). No model was able to predict neuroprotection in 
HT animals. Based on our aggregated data, variability of the neuroprotective effect of HT could therefore not be 
explained by basic experimental variables.
Effect of sex on area loss after HT treatment. Within each individual experiment, no effect of sex 
was seen with regard to degree of damage or neuroprotective effect of HT. However, the picture was distinctly 
different once all the data was analysed together. Median (95% CI) area loss in the NT group was 51.4% (49.2–
56.0%; n = 159) in females, with a trend (p = 0.07) towards lower injury in males (median 45.2%, CI 40.6–51.3%; 
n = 146). In the HT group, median area loss was 40.3% (27.7–45.4%; n = 170) in females, and 42.0% (35.1–47.1%; 
n = 147) in males. The median differences between the NT and HT groups were therefore 11.1% (21.6% neuro-
protection) in females, and 3.2% (7.1% neuroprotection) in males. The overall significant neuroprotective effect 
of HT appeared to be due to a highly significant neuroprotective effect in females (p < 0.001), which compensated 
for a non-significant effect in males (p = 0.07; Fig. 5a). A similar pattern was seen when comparing the animals 
who underwent pathology scoring. In female animals, median (95% CI) global pathology score was 3.6 (3.3–3.9, 
n = 73) in the NT group, and 2.3 (1.4–2.7, n = 83) in the HT group (p < 0.001, Fig. 5c). In males, median global 
pathology score was 3.3 (2.4–3.6, n = 59) in the NT group, and 2.7 (2.0–3.2, n = 62) in the HT group, which was 
not significantly different (p = 0.2, Fig. 5c). Cumulative frequency distribution plots of both area loss (Fig. 5b) 
and global pathology score (Fig. 5d) also show that HT is neuroprotective across the entire range of injury in 
females, with neuroprotection in males centred around moderate scores (~ 20–55% area loss). In female ani-
mals, HT was significantly neuroprotective in all regions (hippocampus, thalamus, basal ganglia, cortex), but no 
region-specific neuroprotection was seen in males (data not shown).
Distribution and consistency of injury. The version of the Vannucci model described here is expected 
to result in a median area loss of around 40% in the NT  group6. Only 3/21 experiments displayed median area 
loss in the NT group below 30% (experiments 2, 4, and 16), and two of those had over 25% median area loss in 
the NT group, suggesting relatively consistent injury across experiments. On visual inspection of the combined 
data from all 622 animals (Fig. 1), a distinct bimodal distribution of injury was seen, with 87.9% of all animals 
(547/622) displaying a percent area loss that was either > 40% or < 20%. In the NT group, 192 of 305 (62.5%) ani-
mals had > 40% area loss, and 83 (27.0%) had < 20% area loss. In the HT group, 161 of 315 (51.1%) animals had 
Figure 4.  Comparison between area loss and global pathology score. (a) Direct comparison of area loss and 
pathology score in the n = 277 (n = 132 NT, n = 145 HT) animals that underwent pathology scoring, representing 
the median injury in the NT and HT groups within each litter from each experiment. Median (95% CI) area loss 
was 51.0% (47.0–54.6%) in the NT group, and 41.3% (31.6–45.6%) in the HT group, with corresponding global 
pathology scores of 3.4 (3.3–3.7) in the NT group, and 2.4 (2.0–2.8) in the HT group. This resulted in a 19.0% 
neuroprotection by HT, compared to 25% neuroprotection when comparing the same animals using global 
pathology score. The resulting ES for HT was 0.42 when using area loss, and 0.51 when using global pathology. 
(b) Global pathology score was linearly correlated with area loss in both the NT  (R2 = 0.94, p < 0.001) and HT 
 (R2 = 0.90) groups (p < 0.001 for both).
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> 40% area loss, with 111 (35.2%) having < 20% area loss. HT resulted in a 16.7% absolute decrease in percentage 
of females with > 40% injury, from 66.7% (NT females) to 50% (HT females), compared to a 7.2% reduction in 
males (58.9% of NT males to 52.7% of HT males). The percentage of animals with < 20% injury also increased by 
a greater extent in females (10.1%, from 26.4% to 36.5%) compared to males (5.2%, from 28.1% to 33.3%). The 
same bimodal injury pattern was seen in the animals analysed for global pathology, with the majority of animals 
having either high (2–4) or low (0–0.5) pathology scores within in each brain region (Supplemental Figure S1).
Discussion
This study provides a novel approach to analysis and reporting of data from a single laboratory and animal model. 
Summarising the data from all our experiments employing HT treatment in the standard Vannucci model of 
moderate HI injury enables us to overcome what Robert Rosenthal termed the “file drawer problem”36, and get 
greater insight into the model itself. He remarked that “for any given research area, one cannot tell how many 
studies have been conducted but never reported”. This is not something that can be solved with a priori power 
calculations and meta-analyses of published  studies22. As with this study, the file drawer problem is likely to be 
particularly pertinent to unpublished pilot studies. The majority of the work summarised here is from pilot stud-
ies that also included non-HT treatment groups that would otherwise have remained unpublished.
Figure 5.  Sex effects of hypothermic neuroprotection. (a) Median (95% CI) area loss in the NT group was 
51.4% (49.2–56.0%; n = 159) in females, and males 45.2% (40.6–51.3%; n = 146) in males. In the HT group, 
median area loss was 40.3% (27.7–45.4%; n = 170) in females, and 42.0% (35.1–47.1%; n = 147) in males. The 
median differences between the NT and HT groups were 11.1% (21.6% neuroprotection) in females, and 
3.2% (7.1% neuroprotection) in males. (b) Cumulative frequency distribution plot of area loss. (c) Median 
(95% CI) global pathology score in females was 3.6 (3.3–3.9, n = 73) in the NT group, and 2.3 (1.4–2.7, n = 83) 
in the HT group. In males, median global pathology score was 3.3 (2.4–3.6, n = 59) in the NT group, and 2.7 
(2.0–3.2, n = 62) in the HT group. (d) Cumulative frequency global pathology score. The cumulative frequency 
plots suggest HT is neuroprotective across the entire range of injury in females, with neuroprotection in males 
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Producing animal models that accurately replicate human disease and provide robust platforms for translat-
ing treatments to the clinic is a notoriously difficult challenge for modern  medicine2,37. One area where this is 
particularly relevant, and has been extensively discussed, is in the translation of neuroscience to the treatment of 
neurological  disease2,22,38,39. Due to the typically-small group sizes and low statistical power seen in most preclini-
cal neuroscience studies, even positive findings are likely to be greatly  exaggerated22. This may be a major reason 
why, when examining experimental treatments for acute stroke, O’Collins et al. found little correlation between 
treatment effect in animal models and subsequent translation to clinical trials in  humans38.
In the field of neuroprotection, the benefit of HT for asphyxiated term infants with moderate-to-severe 
encephalopathy is one of the few successes to  date3. However, the degree of neuroprotection does not appear to 
directly translate from published animal work. In preclinical studies of HT after neonatal HI, successful HT typi-
cally provides around 40–65%  neuroprotection6,7,9,12,40,41. Though the formal pathology scoring used preclinically 
is not directly comparable to outcomes (mortality and neurodevelopmental disability) in children, the magnitude 
of the previously described preclinical effect of HT appears to be significantly greater than that seen in clinical 
 trials3. A large part of this discrepancy may be due to the methodological issues associated with cooling asphyxi-
ated neonates within the optimal time window for neuroprotection where, compared to standardised animals 
models, the exact timing, mechanism, and duration of injury in infants with HIE is often  unknown42,43. This 
includes the heterogeneous clinical scenarios that may contribute to HIE risk including infection, pre-eclampsia, 
gestational diabetes, placental pathologies, intrauterine growth restriction and even maternal stress, in addi-
tion to a perinatal sentinel  event44–50. We found that HT was significantly neuroprotective when administered 
immediately after HI, though the effect was variable across experiments and the overall neuroprotective effect 
was smaller than reported in some previous  studies51. This is to be expected once the overall size of the treatment 
groups  increases22. Importantly, the injury in the NT group was consistent (> 25% area loss in 20/21 experiments), 
suggesting that the majority of the variability was due to different responses to HT itself within each experiment.
One strength of our approach is that the size of the dataset allows for the exploration of a number of factors 
that may influence the degree of injury seen and the response to HT. Interestingly, barometric pressure during 
the morning (surgical and HI period) of each experiment was associated with the degree of injury seen in both 
the HT and NT groups. Though higher barometric pressure tended to result in lower injury, the nadir of injury 
occurred in the 4th quintile of pressure for both groups. However, barometric pressure was not able to accurately 
predict whether animals would experience greater than average injury in the NT group, and was not significantly 
associated with the degree of neuroprotection seen in the HT group. Though P7 weight in the HT group was 
negatively associated with area loss, no clear experimental, operator, or environmental factor could be identified 
that corresponded with experiments where HT was not neuroprotective or the overall degree of neuroprotection 
afforded by HT. We and other have previously shown that individual anatomical factors such as cerebral blood 
flow during HI can significantly affect the final degree of  injury52,53. However, while these individual differences 
are likely to contribute to the variability and pattern of injury seen in the model, they are likely to average out 
with randomisation procedures such as those used in our studies. This suggests that as-yet unidentified factors 
will alter the effect of HT (and potentially other therapies) in a given preclinical experiment, and this variability 
should be expected during experimental planning.
Overall, HT resulted in 17.6% neuroprotection of area loss in the HT group, with a corresponding treatment 
ES of 0.29. In the 277 animals who underwent pathology scoring (the 1–2 animals with median area loss in the 
NT and HT groups within each litter), the ES of HT was 0.42 when comparing area loss, and 0.51 when using 
formal pathology scoring, suggesting a small-to-moderate effect of HT on severity of  injury34. Using formal 
pathology scoring would reduce the number of animals required to see the true ES by at least 30%. Though 
pathology score is more sensitive to the effects of HT at the cellular level, it is interesting to note that the ani-
mals with the highest pathology scores (3.5–4.0) had a wide range of area loss (40–70%), and a combination of 
the two methods may be ideal when assessing the effects of a therapy in more severe injury. Importantly, both 
cumulative frequency plots and dichotomous cut-offs at 20%, 30%, 40%, 50%, and 60% area loss suggested that 
HT was similarly neuroprotective regardless of severity of injury, though the effect does appear to be lost at the 
upper limit of severity (> 70% area loss or global pathology score > 3.5). While preclinical studies are not directly 
comparable to clinical trials, the overall neuroprotective results in the our model are very similar to those seen 
for the ~ 15% absolute reduction in death and major disability (RR 0.75, 0.68–0.83; NNT = 7) in the largest meta-
analyses of clinical trials to  date3,54.
The reduction in more severe injury by HT in this analysis initially appears at odds to our previous work in 
this model, where we have found multiple times that HT is not neuroprotective after severe injury resulting in a 
median area loss of ~ 60%6,20. However, the modification of the insult that resulted in this severe injury included 
increasing the insult temperature from 36 to 37 °C, and increasing the hypoxia time to 150 min6,20. Another 
modification to the insult, using the same hypoxia parameters described in this meta-analysis but pre-exposing 
pups to the Toll-like receptor 2 agonist  PAM3CSK4, also resulted in 60% median area loss in the NT group, but 
significant neuroprotection in the HT group was  seen29. By comparison, pre-sensitisation with E. coli lipopoly-
saccharide negates the neuroprotective effect of HT in this model, despite only “moderate” levels of  injury28,29. 
This suggests that the mechanism of the insult itself (including inflammatory stimulus, temperature, and hypoxia 
time) is likely to dictate whether HT is neuroprotective or not, and not the absolute degree of injury.
As is becoming increasingly reported in the preclinical and clinical literature, a sex difference in response 
to HT was also seen, with a much greater therapeutic effect in females. Previously, when we compared area loss 
or neuropathology scores as outcomes after HI, these have largely been equivalent between the  sexes6,20,24,55, 
though we have seen improved functional outcomes in female animals based on neurobehavioural  testing25,55. 
This sexually-dimorphic effect of HT in our model, and greater benefit in females, is also in line with recent work 
from other  groups56–58. This result is likely to be due to the effects of HT on the variety of cell death pathways 
initiated after cerebral HI. Females appear to more specifically rely on the classical apoptotic pathways of cells 
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10833  | https://doi.org/10.1038/s41598-020-67532-2
www.nature.com/scientificreports/
death, with HT thought to inhibit the apoptotic cascade at multiple  levels59–61. Conversely, male cells appear to die 
via non-apoptotic pathways such as parthanatos caused by the depletion of cellular NAD + due to the activation 
of PARP-1 (Poly [ADP-ribose] polymerase 1)60,62. As a result of sexually-dimorphic mechanisms of injury and 
inflammatory responses, a number of therapies have been found to only benefit one sex or the other, and this is 
an important area for significant future research in the neonatal neuroprotection  field63.
Considering our results and the historical skew towards the use of male animals in neuroscience to mini-
mise variability as a result of the oestrus cycle, it is possible that similar results in other models of brain injury 
may well have prevented some neuroprotective strategies from being fully  investigated64. The large group sizes 
used here might have promoted a regression towards the mean that would also be seen if other studies showing 
improved outcomes in males treated with HT were repeated with more animals. However, it is also important to 
note that rodent studies of HT usually only include a formal HT period of up to 5 h, with some natural ongoing 
hypothermia (rectal temperature < 36 °C) also likely to occur in the nest  afterwards6,27. As temperature control 
is generally poorly-reported in rodent neuroprotection  studies65, comparing the dose an timing of HT to that 
seen in humans is difficult. Despite this, the largest clinical trials of HIE do not appear to have definitively ques-
tioned whether any outcome parameters in asphyxiated infants treated with HT are affected by  sex3,17,18,56,66. 
This information is crucial to the ongoing effort to refine neuroprotective strategies for infants with HIE, and 
with further investigation it may be found that male infants respond less well to standard HT treatment. Due 
the differing mechanisms of injury seen in response to an insult in males and  females60, it is likely that different 
treatment strategies will prove beneficial based on sex as well as underlying mechanism of injury. Males may 
benefit from a different HT temperature or cooling strategy compared to  females67, or see greater benefit after 
the addition of adjunct therapies. For instance, Park et al. found that HT was neuroprotective in combination 
with mesenchymal stem cells (MSCs) in a pre-selected group (> 50% hemispheric involvement on MRI) of male 
rats after HI at  P768. By contrast, Herz et al. found that adding MSCs to HT after unilateral HI in a sex-balanced 
unselected group of P9 mice was  deleterious69. Male animals may also benefit from receiving a different treat-
ment strategy altogether, potentially including sex hormone therapies such as  progesterone70, or prolonged or 
multi-pronged treatments that target oxidative stress  pathways58,71, or the replenishment of NAD + (oxidised 
nicotinamide adenine dinucleotide)62.
Another important aspect of the model that becomes increasingly clear as data is aggregated from multiple 
experiments is the distribution of injury. Two peaks of injury are seen, one above 40% area loss and the other 
below 20% area loss. This suggests two discrete populations of animals with underlying differences that determine 
the initial degree of injury, for instance due to variability in anatomical and physiological blood flow during the 
 insult52,53. Treatment with HT resulted in a 16.7% decrease in percentage of females with > 40% injury, which 
was greater than the 7.2% reduction in males. The percentage of animals with < 20% injury also increased by a 
greater extent in females (10.1%) compared to males (5.2%). This suggests that HT is able to reverse the majority 
of injury in a certain subset of animals initially destined to have > 40% injury, but that this effect is more likely to 
occur in females. More importantly, however, is the way in which the underlying distribution of injury should 
guide analysis of data from this model. It should be assumed that all data from the model must be analysed using 
non-parametric methods, with the bimodal distribution of injury suggesting that most studies in this model are 
dramatically underpowered to detect true treatment effects. Indeed, the analysis presented here is only possible 
due to the much larger group sizes generally presented in preclinical studies. For instance, the protocol for the 
“Optimizing Cooling for Neonatal (HIE)” trial cited a number of preclinical studies, with typical treatment 
group sizes of 4–17  animals66,72, and the largest single treatment group of all of the referenced preclinical studies 
including 31  rats25. These experimental numbers are in stark contrast to the 726 infants that were planned to be 
included in the trial before it was stopped at the halfway point due to lack of likely benefit in the experimental 
groups, and a potential for increased  harm66. While the initial clinical trials of HT were largely based on that 
same body of animal work, the optimisation of an already beneficial treatment protocol will involve the elucida-
tion of much smaller relative effect sizes, which necessitates larger experimental  groups22. Therefore, though the 
three R’s (Replacement, Refinement, and Reduction) are essential to improving the quality and sustainability 
of preclinical  research2, the improved use of animal resources must include ensuring that group sizes are large 
enough to produce adequately-powered results that are more likely to translate to the clinic. Indeed, our analysis 
suggests that to see the true ES of HT in this model, more than 100 animals per group may be required depend-
ing on the outcome measured.
Our study does have several limitations. Compared to the global injury and multi-factorial aetiology of neo-
natal HIE, the unilateral brain-focused injury investigated here cannot fully replicate the complex pathologies 
and systemic organ involvement seen clinically. As mentioned above, we also only performed short-term survival 
with formal pathological scoring in a representative subset of animals. However, this allowed us to examine the 
effects of HT in multiple experiments and in a large number of animals, using an outcome measure (area loss) 
that correlates highly with formal neuropathology. This information then enables us to refine the parameters of 
the model to look for neuroprotective treatments for specific subgroups (i.e. males). As the field moves forward, 
the variability of the Vannucci model clearly suggests that much larger group sizes than have been traditionally 
used should be employed to investigate potential treatments. For in-depth analyses, this will likely require col-
laboration between multiple expert research groups, as well as the promotion of avenues for the collation and 
publication of pilot  data22. To increase the likelihood of successful translation, any promising therapy would 
then be repeated using larger groups sizes and long-term pathological and behavioural  assessments27,55, ideally 
in multiple laboratories. This would then inform work in larger animals such at the piglet or fetal  sheep73. As the 
pipeline applied to promising therapies for term neonatal HIE is fairly robust, one of the most important areas 
for development is the implementation of significantly robust studies in rodents such that later work in larger 
models is focused on the most promising therapies.
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While one benefit of the large aggregated dataset explored here is the ability to draw on increased statisti-
cal power and eliminate some of the effects of inter-experiment variability, it must be acknowledged that each 
individual experiment employed only 10–22 animals per treatment group. As such, it is potentially problematic 
to then suggest that several dozen animals are required per group in future studies examining treatment effects 
in the Vannucci model. However, the main purpose of a meta-analysis is to gain greater insight into a particular 
disease or treatment than is possible from each individual smaller study or trial. With respect to future work, it is 
worth nothing that finding the true effect size of a therapy in a model is not necessarily the same as screening for 
whether or not a therapy has some degree of neuroprotective effect. For the latter purpose, using smaller group 
sizes (n = 20–30 per group) with animals combined from experiments performed over a short period is likely to 
remain worthwhile. The previously published experiments included in this analysis (experiments 7–11) are an 
example of this, where multiple treatment temperatures were assessed in the  model6. These experiments were 
performed over a 2-month period, with each experiment including four of the six final experimental groups. 
In these experiments, injury was fairly variable (37.5–60.7% median area loss in NT group), but the average 
degree of neuroprotection by HT was relatively stable. In four out of five experiments neuroprotection by HT 
was 30.1–37.5%, with 7.5% neuroprotection in the fifth. Importantly, every experiment included a standard 
NT injury group and standard HT treatment group as they are defined in this manuscript. This enabled us to 
more confidently combine experiments as each had control groups for both injury (NT) and treatment (HT). 
Including control groups for both injury and treatment in all experiments, and randomising across all treatment 
groups in all experiments, should be the standard approach. This is particularly important if multiple experi-
ments have to be combined to adequately power an overall study. These studies should also be powered to detect 
the presence of sex-based differences (therefore at least doubling the target group size), and non-parametric 
statistical analysis methods should be used exclusively unless a significant body of outcome data can be shown 
to be normally distributed.
In conclusion, we present our most recent body of work, including all pilot data, examining the neuroprotec-
tive effect of HT in the Vannucci model of unilateral HI brain injury in P7 rats. Hypothermia provided a smaller 
overall neuroprotective effect than previously reported in this model, but this result more accurately reflects those 
seen from clinical trials. The main neuroprotective effect of HT derived from a greater effect in females, and 
future work must be performed to investigate the mechanisms behind the failure of HT in certain scenarios. As 
this model has translated successfully to other animals and clinical HT treatment, it provides a useful potential 
starting point to investigate treatments for subgroups of asphyxiated infants based on sex and severity of injury.
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